Code-N to Provide Secure, Cloud-Based Scientific Intelligence to BioPharma Companies via Exostar’s Life Sciences Identity Hub
Alliance Will Enable BioPharma Companies to Securely Track Competition,
Repurpose Current Drugs, and Improve Drug Safety (Click here to request a demo)
HERNDON, VA, and MENLO PARK, CA, January 18, 2018 – Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Code-N today announced that Code-N will connect its cloud-based solutions to Exostar’s Life Sciences Identity Hub. By joining Exostar’s partner program as an Application Partner, Code-N ensures its Competitive Profiler, Drug Repurposing, and Safety solutions can be securely accessed by organizations and individuals who are members of Exostar’s rapidly expanding life science and healthcare community.
Exostar’s Life Sciences Identity Hub is the scalable, proven solution where asset owners maintain control over access to their applications, which the Identity Hub enforces via Exostar’s Secure Access Manager (SAM). With heightened security for sensitive information and intellectual property, organizations and individuals can collaborate with confidence. Individuals benefit from a single sign-on user experience, which reduces risk and vulnerability while promoting productivity with seamless access to multiple next-generation life science technology solutions like Code-N’s.
“Exostar has become the preferred choice for providing secure cloud-based access to our scientific solutions,” said Randy Haldeman, CEO of Code-N. “By connecting our next-generation products to the Exostar Life Sciences Identity Hub, companies can securely access our solutions to uncover new pathways to cures and provide scientific intelligence for repurposing of drugs and alerting of harmful interactions, faster.”
Exostar’s life science and healthcare community currently includes nearly 15,000 users and 700 organizations, as well as 7 federated organizations and more than 20 federated applications. Global market leaders such as Merck, AstraZeneca, and MedImmune, along with their contract research organization, academic, laboratory, and investigator partners, are reaping the time, cost, and security advantages of the Life Sciences Identity Hub.
“Code-N’s suite of solutions allow life science organizations to instantly track their competitors and new entrants, repurpose drugs, and identify safety issues before going to trials,” said Daniel Pfeifle, Exostar’s Vice President of Sales and Marketing. “By partnering with Exostar and connecting to our Life Sciences Identity Hub, Code-N will increase the potential of these solutions dramatically. At the same time, scientists in the Exostar community will have another valuable solution at their fingertips.”
Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain. Exostar supports the complex trading needs of many of the world’s largest companies in aerospace and defense, life sciences, and other industries. Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 100,000 companies in 150 countries worldwide. The Exostar community includes market leaders such as AstraZeneca, BAE Systems, Bell Helicopter, The Boeing Company, Computer Sciences Corporation, Lockheed Martin Corp., Merck, Newport News Shipbuilding, Northrop Grumman, Raytheon Co. and Rolls-Royce. For more information, please visit www.exostar.com.
Code-N is a secure cloud computing company that delivers next-generation bioinformatics subscription products to the life science industry to solve Big Data problems that cannot be solved with currently available keyword-based Internet software and search technologies. Its patent-pending technology instantly uncovers advance insights and pathways to scientific intelligence and new drug targets, based on all relevant industry data simultaneously. The technology also powers drug repurposing and warns about negative interactions proactively. The company was featured as a visionary in “Life Science Trends – 2014” and selected as a “20 Most Promising Biotech Solutions Provider” in 2015.